Basaglar will also undercut Sanofi’s longer ... by 21% and Tresiba (insulin degludec) an ultra long-acting insulin, by 28%. The prices that patients will pay depends on their insurance scheme ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Approved at the beginning of 2016, US revenues of the cheaper competitor, Basaglar ... its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

Basaglar is used to manage blood sugar levels in diabetes by providing a long-acting insulin injection once daily, helping regulate glucose levels throughout the day and night. In June 2024 ...